- Home
- ITCI
as 02-04-2025 4:00pm EST
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | BEDMINSTER |
| Market Cap: | 13.5B | IPO Year: | N/A |
| Target Price: | $103.62 | AVG Volume (30 days): | 5.8M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $62.78 - $128.00 | Next Earning Date: | 02-20-2025 |
| Revenue: | $613,728,000 | Revenue Growth: | 46.08% |
| Revenue Growth (this year): | 48.43% | Revenue Growth (next year): | 38.10% |
Stock Insider Trading Activity of Intra-Cellular Therapies Inc. (ITCI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mates Sharon | ITCI | Chairman and CEO | Dec 4 '24 | Sell | $85.10 | 102,697 | $8,722,500.92 | 1,093,662 | |
| Halstead Michael | ITCI | President | Nov 12 '24 | Sell | $89.27 | 41,583 | $3,692,100.03 | 7,764 |
Latest Intra-Cellular Therapies Inc. News
ITCI Breaking Stock News: Dive into ITCI Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119
Insider Monkey
10 days ago
Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now
Insider Monkey
12 days ago
Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now
The Wall Street Journal
13 days ago
Biotech Venture Investors Optimistic, But Uncertainties Persist
GuruFocus.com
13 days ago
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Yahoo Finance
14 days ago
Downside risk from talc lawsuit, Stelara generic competition is 'manageable': JNJ CFO Joe Wolk
Yahoo Finance
14 days ago
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
MT Newswires
14 days ago
RBC Downgrades Intra-Cellular Therapies to Sector Perform From Outperform on Proposed Sale to Johnson & Johnson
Compare ITCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITCI Intra-Cellular Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.